Infinity Pharmaceuticals | INFI - Operating Profit


Infinity Pharmaceuticals reported $-10.12M in Operating Profit for its fiscal quarter ending in June of 2023.





Operating Profit Change Date
AbbVie USD 4.73B 1.08B Mar/2026
Alterity Therapeutics Limited AUD -8.07M 302.4K Dec/2025
Amgen USD 3.83B 130M Mar/2026
AstraZeneca USD 7.11B 4.14B Mar/2026
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Cipla INR 9.77B 6.21B Dec/2025
Clal Biotechnology ILS -1.74M 7.46M Dec/2022
Compugen USD 56.04M 63.93M Dec/2025
CSL USD 2.64B 1.97B Dec/2025
Eisai JPY 20.03B 6.36B Dec/2025
Eli Lilly USD 9.78B 792M Mar/2026
Gilead Sciences USD 2.68B 284M Mar/2026
GlaxoSmithKline GBP 2.29B 856M Mar/2026
Grifols EUR 320.55M 91.01M Dec/2025
Incyte USD 324.17M 59.7M Mar/2026
Infinity Pharmaceuticals USD -10.12M 1.39M Jun/2023
Ionis Pharmaceuticals USD -118M 97M Mar/2026
J&J USD 6.62B 1.03B Mar/2026
Novartis USD 4.24B 171M Mar/2026
Pfizer USD 4.99B 340M Mar/2026
Plus Therapeutics USD -5.74M 1.26M Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
TG Therapeutics USD 34.8M 15.7M Mar/2026